insights_auto
Why is EBS up 3,67%?
Dive Deeperchevron_right
EBS:NYSE
Emergent Biosolutions Inc
USD 7,06
arrow_upward
+3,67%(+0,25) 1D
USD 7,01
arrow_downward
-0,71% (-0,050)bedtimeAfter hours
Closed: 9 Okt., 16:00:07 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EBS...
Open
USD 6,73
High
USD 7,06
Low
USD 6,60
Mkt. cap
361,99 m
Avg. vol.
1,18 m
Volume
850,96 k
52-wk high
USD 14,06
52-wk low
USD 4,36
EPS
-USD 3,51
Beta
2,28
Shares outstanding
51,27 m
No. of employees
900
Open
USD 6,73
High
USD 7,06
Low
USD 6,60
Mkt. cap
361,99 m
Avg. vol.
1,18 m
Volume
850,96 k
52-wk high
USD 14,06
52-wk low
USD 4,36
EPS
-USD 3,51
Beta
2,28
Shares outstanding
51,27 m
No. of employees
900
News stories
From web sources and news partners
https://www.dars.gov.et/
·
1 week gelede
EBS Q2 2026 Earnings: EPS Smashes Estimates by 440% as Shares Edge Higher - Forward EPS Estimate
Profile
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
About Emergent Biosolutions Inc
CEORobert G. Kramer Sr. | Joseph C. Papa
Employees900
Founded05 Sep. 1998
HeadquartersRockville, Maryland, Verenigde State van Amerika
Sector-
Websiteemergentbiosolutions.com